EGFR and non-small cell lung carcinoma: REGN1400, (Table 4) an anti-HER3 antibody, increased sensitivity to anti-EGFR treatment in HNSCC in xenografts models.[129] A clinical trial showed that REGN1400 is safe and well tolerated alone or in combination with erlotinib or cetuximab in patients with advanced CRC, HNSCC and NSCLC (NCT01727869).[130]